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Abstract 
Introduction 
Previous studies have identified cholesterol as an important regulator of breast cancer 
development. High-density lipoprotein (HDL) and its cellular receptor, scavenger receptor 
class B type I (SR-BI) have both been implicated in the regulation of cellular cholesterol 
homeostasis, but their functions in cancer remain to be established. 
Methods 
In the present study, we have examined the role of HDL and SR-BI in the regulation of 
cellular signaling pathways in breast cancer cell lines and in the development of tumor in a 
mouse xenograft model. 
Results 
Our data show that HDL is capable of stimulating migration and can activate signal 
transduction pathways in the two human breast cancer cell lines, MDA-MB-231 and MCF7. 
Furthermore, we also show that knockdown of the HDL receptor, SR-BI, attenuates HDL-
induced activation of the Phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt) 
pathway in both cell lines. Additional investigations show that inhibition of the PI3K 
pathway, but not that of the mitogen-activated protein kinase (MAPK) pathway, could lead to 
a reduction in cellular proliferation in the absence of SR-BI. Importantly, while the 
knockdown of SR-BI led to decreased proliferation and migration in vitro, it also led to a 
significant reduction in tumor growth in vivo. Most importantly, we also show that 
pharmacological inhibition of SR-BI can attenuate signaling and lead to decreased cellular 
proliferation in vitro. Taken together, our data indicate that both cholesteryl ester entry via 
HDL-SR-BI and Akt signaling play an essential role in the regulation of cellular proliferation 
and migration, and, eventually, tumor growth. 
Conclusions 
These results identify SR-BI as a potential target for the treatment of breast cancer. 
Introduction 
Breast cancer is estimated to have affected over 200,000 women in the United States in 2012 
and will be responsible for approximately 40,000 deaths, making it the second leading cause 
of cancer deaths [1]. Recently, attention has focused on examining the role of components of 
the diet, such as cholesterol, in breast cancer development. Plasma cholesterol levels are often 
lower in patients with advanced lung [2] and breast cancers [3-5], a phenomenon known as 
the “preclinical effect of cancer” [6]. This effect is believed to be consequential and not 
causal [6] but does suggest a role for cholesterol in cancer. Several epidemiologic studies 
have shown a positive correlation between elevated high density lipoprotein cholesterol 
(HDL-C) levels and breast cancer risk [5,7-9], and recent data have corroborated this claim 
[10-16]. In vivo works have suggested that hypercholesterolemia induced by diet and/or 
genetic background leads to increased tumor burden and metastasis in murine breast cancer 
models [10,12]. In vitro analyses have shown that human breast cancer cell lines exhibit 
increased proliferation and migration in the presence of HDL [11,13,15-17]. The effect of 
cholesterol on breast cancer may be attributed to several of its properties and functions. 
Cholesterol is the precursor of bioactive steroid hormones such as estrogen. It is also 
necessary for the formation of plasma membrane microdomains known as lipid rafts [18]. 
Lipid rafts are believed to organize signaling molecules in the plasma membrane and, as a 
result, have been implicated in the development of human cancers [19]. Therefore, 
cholesterol may play an essential role in the regulation of tumor growth [20,21]. 
The HDL lipoprotein is an important carrier of plasma cholesterol and can function as a 
signaling molecule by initiating MAPK and AKT signaling pathways and stimulate migration 
in endothelial cells [22-24]. The activation of these signaling pathways is dependent on HDL 
binding to the HDL receptor, the scavenger receptor class B, type I (SR-BI) and subsequent 
lipid transfer to the cell [25-27]. SR-BI functions as the HDL receptor and has been shown to 
mediate the selective transfer of cholesteryl ester from HDL molecules to cells in a process 
known as the selective HDL-cholesteryl ester uptake [28]. Its role in the development of 
atherosclerosis has been well documented [28], but its role in cancer has not been extensively 
investigated. Nevertheless, SR-BI has been implicated in prostate [29] and breast cancer 
[15,30]. In the case of breast cancer, SR-BI protein levels were found to be increased in 
malignant tissue samples compared to the normal surrounding tissue [30]. 
In the present study, we have examined the role of HDL and SR-BI in the regulation of 
cellular signaling pathways in breast cancer cell lines and in the development of tumors in a 
mouse xenograft model. Our data show that HDL can stimulate migration and can activate 
signal transduction pathways in the two human breast cancer cell lines, MDA-MB-231 and 
MCF7. Furthermore, we also show that knockdown of the HDL receptor, SR-BI, attenuates 
HDL-induced activation of the MAPK and PI3K/Akt pathways in both cells lines. A more 
detailed analysis revealed that SR-BI regulates signaling pathways via Akt activation, and the 
regulation of SR-BI expression or activity could limit tumor development in a mouse model. 
Methods 
Materials 
The following antibodies were used: SR-BI was from Novus Biologicals, Inc. (Littleton, CO). 
CD31 antibody was from Abcam, Inc. (Cambridge, MA). Phospho-Erk1/2 (T202/Y204), 
Erk1/2, Phospho-Akt (S473), and Akt were from Cell Signaling Technology, Inc. (Beverly, 
MA). GAPDH was from Fitzgerald Industries International (Acton, MA), and β-Actin was 
from Sigma-Aldrich Corp. (St. Louis, MO). Anti-mouse secondary antibody was from 
Thermo Fisher Scientific, Inc. (Rockford, IL) and anti-rabbit secondary antibody was from 
BD Biosciences (San Jose, CA). The signaling inhibitors U0126 and LY294002 were from 
Cell Signaling Technology and Sigma-Aldrich, respectively. BLT-1 was from EMD 
Millipore (Billerica, MA). 
Cell culture 
MCF7 cells were obtained from the American Tissue Culture Collection (ATCC) (Manassas, 
VA) and MDA-MB-231 cells were as previously described [31]. MDA-MB-231 and MCF7 
cells were grown in Dulbecco’s modified Eagle’s media (DMEM) containing 10% Fetal 
Bovine Serum (FBS) in an incubator kept at 37°C with 5% CO2. 
Purification of lipoproteins 
Human plasma was obtained from adult female volunteers. Approval for the use of human 
plasma was obtained from the Office of Human Research at Thomas Jefferson University, 
and consent was obtained from the volunteers for the use of their plasma samples. 
Lipoproteins [LDL (1.019-1.063 g/mL), HDL2 (1.063-1.125 g/mL), HDL3 (1.125-1.21 g/mL] 
were separated by density gradient ultracentrifugation as previously described [32]. HDL3 
was dialyzed against PBS, 0.5 mM EDTA, 1% NaN3. In experiments with MCF7 cells, 
lipoproteins were stripped of estrogens with activated charcoal to remove endogenous steroid 
hormones, as previously described [16]. 
Migration and invasion assays 
Migration was assayed using modified, non-coated Boyden chambers from BD Biosciences 
(San Jose, CA). Both MDA-MB-231 and MCF7 cells were cultured in 10-cm dishes in 
DMEM containing 10% FBS. Cells were harvested, counted, and washed three times with 
PBS. Cells were resuspended in DMEM containing 1% BSA, and 5.0x104 cells were added to 
the upper chambers. The bottom chambers contained 1% FBS or 100 µg/mL lipoprotein in 
1% BSA. Cells were incubated at 37°C overnight. At the end of the experiment, upper 
chambers were swabbed with a cotton swab to remove non-migrating cells, stained with 
crystal violet and quantified using phase contrast microscopy. Migration was quantified by 
counting the number of cells in 5 separate fields at 10× magnification. Invasion assays were 
performed as described above for transwell migration assays but used matrigel-coated 
Boyden chambers (BD Biosciences). The upper chambers contained cells in 1% BSA and the 
bottom chambers contained 1% FBS or 100 µg/mL lipoprotein in 1% BSA. 
Immunoblot analysis 
Cells were lysed in radio-immunoprecipitation assay (RIPA) buffer containing protease and 
phosphatase inhibitors from Roche Applied Science (Indianapolis, IN) and Sigma-Aldrich 
Corp., respectively, prepared and analyzed as previously described [33]. Briefly, proteins 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Membranes 
were blocked in 5% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBS-T). 
Primary antibodies were diluted in 5% BSA in TBS-T and incubated for either 1 hour at room 
temperature or overnight at 4°C. Membranes were washed three times in TBS-T, and 
incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature. Membranes were washed three times in TBS-T, and visualized using Pierce 
Chemiluminescent Substrate from Thermo Fisher Scientific, Inc. 
Knockdown of SR-BI 
MDA-MB-231 and MCF7 stably transfected cell lines were produced by lentiviral 
transduction. Lentiviral particles containing a pool of 3 short hairpin RNA (shRNA) 
constructs targeted against SR-BI were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). Control lentiviral particles containing scrambled shRNA sequences were 
also purchased from Santa Cruz. Cells were transduced with the lentiviral particles according 
to manufacturer’s protocol. Two days post-transduction, target cells containing either control 
shRNA (shCTL) or shRNA against SR-BI (shSRBI) were selected using 2.5 µg/mL 
puromycin. Successful knockdown was verified by immunoblot analysis. 
Cholesterol content determination 
Cells were grown to confluence in 10-cm dishes in the presence of complete media (DMEM, 
10% FBS). In half of the plates cholesterol was extracted with isopropanol. The extract was 
dried down in glass tubes under nitrogen and re-solubilized in a smaller volume of 
isopropanol. Cholesterol content was determined using the Cholesterol E kit from Wako 
Chemicals USA, Inc. (Richmond, VA) as per the manufacturer’s instructions. In the other 
plates, cells were lysed with 0.5 NaOH, and lysates were collected. Protein concentration was 
determined by the bicinchoninic acid assay (BCA) from Thermo Fisher Scientific as per the 
manufacturer’s instruction. Total cellular cholesterol levels were calculated by dividing the 
total cholesterol by the total protein per dish. 
3H-Thymidine incorporation proliferation assays 
Cell proliferation was measured by [3H]-thymidine incorporation to assess DNA synthesis 
and proliferation. MDA-MB-231 cells were seeded (5.0x104 cells/well) in 12-well plates in 1 
mL of DMEM containing 10% fetal bovine serum (FBS) and grown overnight. The following 
day, media was aspirated, cells were washed twice with PBS and were serum-starved with 
1% fatty acid free bovine serum albumin (BSA) for 1 hour. Media containing FBS, 1% BSA, 
or 1% BSA with lipoproteins (100 µg/mL) and 1 µCi/mL of 3H-thymidine from Perkin Elmer 
(Waltham, MA) was added to cells. Cells were incubated for 6 hours at which time media 
was removed, cells were washed twice with PBS and incubated in 10% trichloroacetic acid to 
precipitate DNA. Cells were solubilized in 0.1 M NaOH and 1% SDS. Radioactivity was 
measured by liquid scintillation counting. Protein concentration was determined using the 
BCA assay. 
Tumor studies 
All mice were housed and maintained in a barrier facility at the Kimmel Cancer Center at 
Thomas Jefferson University. Mice used in this study were athymic nude mice obtained from 
Taconic (Hudson, NY). Animal protocols used for these studies were approved by the 
Institutional Animal Care and Use Committee of Thomas Jefferson University. MDA-MB-
231 (106 ) cells containing either shRNA targeted against SR-BI (shSRBI) or control shRNA 
containing scrambled shRNA (shCTL) were subcutaneously injected in the flank of 7–9 week 
old nude mice. MCF7 cells (5 × 106) were orthotopically injected into the mammary fat pad 
of 9 week-old athymic nude mice implanted with slow release 17β-estradiol pellets 
(0.36mg/pellet, 60 days) from Innovative Research of America (Sarasota, FL). Four weeks 
post-injection, tumors were excised, weighed, and the volume was determined using the 
formula (width2 x length)/2. Half of each tumor was flash frozen and stored at −80°C and 
subsequently homogenized and lysed in RIPA buffer for immunoblot analysis as previously 
described [33]. The other half was fixed in formalin for 24 hours and then used to prepare 
paraffin-embedded sections. 
Immunohistochemical analysis 
Paraffin-embedded tumor sections were deparaffinized in xylene and rehydrated. Antigen 
retrieval was performed in 10 mM citrate buffer pH6 for 10 min using a pressure cooker. 
Endogenous peroxidase activity was blocked with 3% H2O2, and sections were blocked in 
10% goat serum obtained from Vector Laboratories, Inc. (Servion, Switzerland) and 
incubated with primary antibody overnight at 4°C. Sections were washed three times with 
PBS, incubated with biotinylated secondary antibody for 30 minutes followed by HRP-
conjugated streptavidin for 30 minutes using a Streptavidin-HRP kit from Dako North 
America, Inc. (Carpinteria, CA). After 3 washes in PBS, the presence of bound antibody was 
visualized using 3,3′ diaminobenzidine (DAB). Slides were counterstained with hematoxylin, 
dehydrated, and mounted with coverslips. 
TUNEL assay 
Apoptosis was measured by TUNEL assay using the TUNEL-based ApopTag Peroxidase In 
Situ Apoptosis Detection Kit from Millipore (Temecula, CA) as per manufacturer’s 
instructions. Briefly, paraffin-embedded tumor sections were de-paraffinized and rehydrated. 
Sections were treated with 20 µg/ml proteinase K from Roche Applied Science (Indianapolis, 
IN) for 15 min at room temperature and washed, and peroxidase activity was blocked by 
incubation in 3% hydrogen peroxide for 5 min. Sections were then incubated with 
equilibration buffer, followed by incubation in TdT enzyme for 1 h at 37°C. After washing, 
sections were incubated with HRP-conjugated antibody directed again digoxigenin for 30 
min at RT, washed, and apoptotic positive cells were visualized using DAB. The percentage 
of apoptotic cells was quantified by dividing the number of TUNEL positive cells by the total 
number of cells observed in four distinct fields per section. 
Statistical analyses 
All values are expressed as the mean ± standard deviation (SD). The Prism 4.0 program 
(GraphPad Software, Inc., San Diego, CA) was used for statistical analysis. Statistical 
significance was examined using the Student’s t test or ANOVA when appropriate. 
Results 
HDL3 stimulates migration and activates Akt and Erk1/2 in MCF7 and MDA-
MB-231 cells 
Previous studies have shown that HDL can induce migration of endothelial cells [24]. In 
cancer, tumor cell migration represents the initial step associated with the development of 
metastasis [34]. To examine the effect of HDL on breast cancer cell migration, we studied the 
effect of lipoproteins on the migration of two breast cancer cell lines, MCF7 and MDA-MB-
231. Interestingly, we found that when HDL3 was used as the chemoattractant, it induced 
migration of both MCF7 and MDA-MB-231 cells by 3.5 and 61 fold, respectively, compared 
to the controls (CTL) as a chemoattractant (Figure 1A and B). Interestingly, LDL had no 
effect on the migration of neither MCF7 nor MDA-MB-231 cells (Figure 1A and B). Since 
lipoproteins, specifically HDL, can act as signaling molecules in endothelial cells and 
prostate cancer cells and activate Akt and MAPK pathways [23,35], we examined their effect 
on signaling in MCF7 and MDA-MB-231 cells. However, HDL3 (100µg/mL) stimulated the 
activation of Erk1/2 and Akt in both MCF7 and MDA-MB-231 cells (Figure 1C). A modest 
increase in the phosphorylation of Erk1/2 was observed in MDA-MB-231 cells after 30 
minutes of incubation with HDL3. However, a more robust and quicker response was 
observed in MCF7 cells (Figure 1C). Additionally, HDL3 rapidly activated Akt in both cell 
lines, an effect that was prolonged in MCF7 cells (Figure 1C). These results indicate that 
HDL3 can function as a signaling molecule in these two breast cancer cell lines. LDL had a 
modest effect on Akt activation, and no effect on Erk1/2 activation in neither MDA-MB-231 
nor MCF-7 cells was observed (Figure 1D). 
Figure 1 HDL3 induces migration and acts as a signaling molecule in MDA-MB-231 and 
MCF7 cells. A. and B. Migration of MCF7 (A.) and MDA-MB-231 (B.) cells was induced 
by HDL3. Migration of MCF7 and MDA-MB-231 cells was increased when HDL3, but not 
LDL, was used as a chemoattractant compared to CTL (1% BSA alone) in Boyden Chamber 
assays. Stained cells were quantified using phase contrast microscopy. Columns represent the 
mean number of migrated cells; bars represent ± standard deviation (SD) (n=3). The results 
obtained with CTL and HDL3 groups are significantly different. There was no statistical 
difference between CTL and LDL groups. (A. *P< 0.05 Student’s t test, B. **P<0.01, versus 
1% BSA by Student’s t test). Results shown are representative of three independent 
experiments. C. MDA-MB-231 and MCF7 cells were incubated for the indicated amounts of 
time with 100 µg/mL HDL3. Whole cell lysates were analyzed by Western blotting for the 
indicated proteins. The arrow indicates the protein corresponding to phospho-Akt. Results are 
representative of 3 independent experiments. D. MDA-MB-231 and MCF7 cells were 
incubated for the indicated amounts of time with 100 µg/mL LDL. Whole cell lysates were 
analyzed by Western blotting for the indicated proteins. The arrow indicates the protein 
corresponding to phospho-Akt. Results are representative of 3 independent experiments. 
Knockdown of the HDL receptor, SR-BI, attenuates the effects of HDL3 on 
signaling in MDA-MB-231 and MCF7 cells 
In the following experiments, we examined the effect of downregulating the HDL receptor, 
SR-BI, on signaling in MDA-MB-231 and MCF7 cells. As demonstrated in Figure 2, we 
were able to successfully downregulate SR-BI in both MDA-MB-231 cells (Figure 2A) and 
MCF7 cells (Figure 2B). Knockdown of SR-BI was achieved by stable transduction of a pool 
of lentiviral particles containing shRNA sequences specific for SR-BI (shSRBI). shCTL cells 
were created by stable transduction of lentiviral particles containing a scrambled version of 
the shRNA. Knockdown of SR-BI was assessed by western blot analysis. In MDA-MB-231 
cells, SR-BI expression was reduced by 5.3 fold and in MCF7 cells, SR-BI expression was 
reduced by 4.0 fold (Figure 2A). To determine the role of SR-BI on the regulation of 
signaling pathways, both shCTL and shSRBI MDA-MB-231 and MCF7 cells were serum 
starved overnight and then incubated in media containing 10% FBS for 30 minutes or 100 
µg/mL of HDL3 for 0, 5, 15 and 30 minutes, as indicated. We found that the activation of Akt 
was greatly reduced in the shSRBI cells compared to the shRNA control cells. Similar results 
were obtained with both MDA-MB-231 and MCF7 cell lines in the presence of FBS (lanes 1 
and 6 in both Figures 2A and 2B). Consistent with the results presented in Figure 1C, HDL3 
was able to stimulate the activation of Akt in both cell lines in a time-dependent manner. 
However, activation of Akt in shSRBI MDA-MB-231 cells was greatly reduced when 
stimulated by HDL3 for 15 and 30 minutes (Figure 2A, lanes 9 and 10), compared to the Akt 
activation observed in shCTL MDA-MB-231 cells when stimulated by HDL3 for the same 
periods of time (Figure 2A, lanes 4 and 5). Similar results were obtained in MCF7 cells. In 
that case, Akt activation was reduced in the shSRBI MCF7 cells when stimulated by HDL3 
for 15 and 30 minutes (Figure 2B, lanes 9 and 10), compared to shCTL MCF7 cells 
stimulated by HDL3 for the same periods of time (Figure 2B, lanes 4 and 5). Finally, Erk1/2 
appeared to be constitutively active in MDA-MB-231 cells (Figure 2A, lanes 1–10). 
However, almost no change in Erk1/2 activation was detected in shSRBI MDA-MB-231 cells 
treated with HDL3 for 30 minutes (Figure 2A, lane 10) compared to shCTL MDA-MB-231 
treated with HDL3 for 30 minutes (Figure 2A, lane 5). This effect was in contrast with 
observations made with MCF7 cells (Figure 2B). In shCTL MCF7 cells, HDL3 rapidly 
stimulated Erk1/2 activation, reaching a peak at 5 minutes (Figure 2B, lane 3) but 
maintaining a sustained effect at 30 minutes (Figure 2B, lanes 4 and 5). Activation of Erk1/2 
in shSRBI MCF7 cells followed a similar pattern, but the intensity of activation was greatly 
reduced (Figure 2B, lanes 7–10). These results suggest that downregulation of SR-BI in 
MDA-MB-231 and MCF7 cells attenuates signaling via the AKT and MAPK pathways. 
Additionally, our results also show that the interaction between HDL and SR-BI regulates 
activation of these signaling pathways. Finally, the effect of LDL was also tested in these 
cells lines. Results presented in Figure 2C and D demonstrate that the downregulation of SR-
BI in MDA-MB231 and MCF7 cells had no effect on the regulation of Akt and Erk1/2 
activation by LDL. 
Figure 2 Knockdown of SR-BI attenuates HDL3-induced signal transduction in MDA-
MB-231 and MCF7 cells. A, B. MDA-MB-231 and MCF7 cells were stably transduced by 
lentiviruses carrying either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells 
were incubated with either 10% FBS for 30 minutes or with 100 µg/mL HDL3 for the 
indicated times. Whole cell lysates were analyzed by Western blot for the indicated proteins. 
The arrow indicates the protein corresponding to phospho-Akt. GAPDH was used as loading 
control. C, D. MDA-MB-231 and MCF7 cells were stably transduced by lentiviruses carrying 
either shRNA against SR-BI (shSRBI) or control shRNA (shCTL). Cells were incubated with 
either 10% FBS for 30 minutes or with 100 µg/mL LDL for the indicated times. Whole cell 
lysates were analyzed by Western blot for the indicated proteins. The arrow indicates the 
protein corresponding to phospho-Akt. GAPDH was used as loading control. Note that, in 
panel C, image was spliced (between line 5 and 6) to eliminate an irrelevant line. 
Knockdown of the HDL receptor, SR-BI, inhibits proliferation and migration 
of MDA-MB-231 cells 
We observed decreased signaling in shSRBI MDA-MB-231 cells compared to shCTL MDA-
MB-231 cells in the presence of FBS. Therefore, we used media containing 10% FBS for the 
remainder of the experiments described below. FBS contains large amounts of lipoproteins 
and provides suitable ligands for SR-BI. Previous studies have shown that expression of SR-
BI in COS-7 cells significantly increased cholesterol mass in these cells compared to control 
vector-transfected cells [36]. To determine if cellular cholesterol homeostasis was affected by 
the downregulation of SR-BI, we quantified the cholesterol content of shCTL and shSRBI 
MDA-MB-231 cells. Under basal conditions, shCTL MDA-MB-231 cells contained a 
significantly greater (1.3-fold increase) (P<0.01) total cholesterol content compared to 
shSRBI MDA-MB-231 cells (Figure 3A). 
Figure 3 Knockdown of the HDL receptor, SR-BI, inhibits proliferation, migration, and 
invasion of MDA-MB-231 cells. A. Cholesterol content of shCTL and shSRBI MDA-MB-
231 cells. Cholesterol was extracted from cells with isopropanol, and total cholesterol was 
measured enzymatically using a colorimetric assay. Protein concentration was also 
determined, and total cellular cholesterol content was expressed as the amount of cholesterol 
per milligram of protein. Columns represent the mean cholesterol content and bars represent 
± SD. shCTL MDA-MB-231 cells displays significantly more cholesterol than shSRBI 
MDA-MB-231 cells (**P<0.01 by student’s t test). B. Knockdown of SR-BI inhibits 
proliferation of MDA-MB-231 cells. MDA-MB-231 cells containing control shRNA (shCTL) 
or shSRBI were incubated in the presence of 3H-thymidine for 6 hours in DMEM containing 
10% FBS. Proliferation was measured by 3H-thymidine incorporation. Columns represent the 
mean 3H-Thymidine incorporation (cpm/µg protein); bars represent ± (SD). The results 
obtained for shCTL and shSRBI cells are significantly different (*P<0.01 by student’s t test). 
Results are representative of three independent experiments. C. Knockdown of SR-BI 
reduces cellular migration. Cellular migration of shCTL and shSRBI MDA-MB-231 cells 
was assessed for 24h in a Boyden Chamber using 1% FBS as a chemoattractant. Columns 
represent the mean number of migrated cells from three independent experiments, bars 
represent ± standard deviation (SD), (n=12). The results obtained from the shCTL and 
shSRBI groups are significantly different (*P<0.05 versus shCTL, as determined by 
student’s t test). D. Knockdown of SR-BI leads to a marginally significant reduction in 
cellular invasion. Invasion of shCTL and shSRBI MDA-MB-231 cells was assessed by 
matrigel-coated Boyden Chamber Assays using 1% FBS as a chemoattractant. Columns 
represent the mean number of invaded cells from three separate experiments (n=12); bars 
represent ± SD (P=0.0517, Student’s t test). 
Previous studies have shown that a mutant of SR-BI inhibits proliferation of the luminal B 
subtype of human breast cancer cells, MCF7, in the presence of HDL [30]. To further 
investigate the role of SR-BI in a triple negative (lacking the estrogen receptor (ER), 
progesterone receptor (PR), and Her2) basal B subtype breast cancer cell line, we determined 
the effect of knocking down SR-BI on the proliferation of MDA-MB-231 cells. The 
proliferation of shSRBI MDA-MB-231 cell was reduced by 2.0 fold compared to the 
proliferation observed with shCTL MDA-MB-231 cells (P<0.01) (Figure 3B). Knockdown of 
SR-BI also significantly reduced cellular migration (P<0.05) by 1.65 fold (Figure 3C). 
Finally, a reduction of SR-BI protein levels was associated with a marginally significant 
reduction of the ability of MDA-MB-231 cells to invade (Figure 3D) (P=0.0517). 
Pharmacological inhibition of SR-BI reduces proliferation and signal 
transduction in MDA-MB-231 cells 
To further elucidate the inhibitory effect of SR-BI ablation on proliferation and signal 
transduction obtained by molecular biological means, we treated cells with the 
pharmacological inhibitor of SR-BI, BLT-1 [37]. Previous work has identified BLT-1 as a 
specific inhibitor of SR-BI function. BLT-1 has been shown to act by blocking the transfer of 
lipids from HDL particles to cells [37]. The IC50 for this compound was determined to be 50 
nM [37]. The ability of BLT-1 to regulate proliferation was evaluated in the presence of 
varying concentrations of this inhibitor. Accordingly, BLT-1 could inhibit growth of shCTL 
MDA-MB-231 cells in a dose-dependent manner (Figure 4A). At doses over 50 nM, BLT-1 
treatment could significantly decrease proliferation of shCTL MDA-MB-231 cells compared 
to the control untreated cells (P<0.001 for concentrations of 50 nM, 75 nM, and 100 nM 
compared to shCTL MDA-MB-231 incubated with 0 nM BLT-1). Importantly, there was no 
significant effect of BLT-1 treatment on the proliferation of shSRBI MDA-MB-231 cells: 
Proliferation of shSRBI cells treated with concentrations of BLT-1 between 0.1nM and 
100nM were not statistically different from that of vehicle-treated shSRBI cells. Interestingly, 
there was also no significant difference between shCTL MDA-MB-231 cells treated with 
BLT-1 at doses above 20nM and vehicle-treated (0nM) shSRBI MDA-MB-231 cells. Taken 
together, these results suggest that down regulation or pharmacological inhibition of SR-BI 
have similar effect on MDA-MB-231 proliferation. 
Figure 4 Inhibition of SR-BI by the small molecule BLT-1 inhibits proliferation of 
MDA-MB-231 cells. A. Pharmacological inhibition of SR-BI in MDA-MB-231 cells inhibits 
cellular proliferation. MDA-MB-231 shCTL cells were incubated in the presence of the 
indicated doses of BLT-1 and 3H-thymidine added to the culture media for six hours. At this 
time, the assay was stopped, and lysates were collected. Columns represent the mean 3H-
thymidine incorporation (cpm/µg protein); bars represent ±SD. Results obtained with shSRBI 
MDA-MB-231 CTL (0 nM BLT-1) are significantly different from those obtained with 
shCTL 0 nM BLT-1 (CTL) (a, P<0.001), shCTL 0.1 nM BLT-1 (b, P<0.001), and shCTL 
1.0 nM (c, P<0.05). Results obtained with shCTL MDA-MB-231 CTL (0nM BLT-1) were 
significantly different from those obtained with shCTL 50 nM BLT-1 (d, P<0.001), shCTL 
75 nM BLT-1 (e, P<0.001), and shCTL 100 nM (f, P<0.001). Significance was determined 
by one-way ANOVA with Tukey’s post-test analysis. B. Pharmacological inhibition of SR-
BI attenuates signaling in MDA-MB-231 cells. Western blot analysis was performed with 
extracts obtained from shSRBI MDA-MB-231 cells treated with vehicle, shCTL MDA-MB-
231 cells treated with vehicle, and shCTL MDA-MB-231 cells treated with BLT-1 (50 nM). 
Cells were serum starved overnight, incubated with vehicle alone or BLT-1 for 3 hours, and 
then treated with 10% FBS for 30 minutes. 
We also examined the effect of BLT-1 on signal transduction in these cells. In agreement 
with the finding described in Figure 2A, Akt activation in shSRBI MDA-MB-231 cells 
treated with FBS for 30 minutes was reduced compared to shCTL MDA-MB-231 cells 
(Figure 4B). Similar results were obtained with shCTL MDA-MB-231 cells with treated 
BLT-1. Akt activation was reduced in the treated shCTL MDA-MB-231 cells compared to 
untreated control cells. Finally, SR-BI knockdown or pharmacological inhibition had no 
effect on Erk1/2 activation (Figure 4B) compared to the control cells. A statistical difference 
between untreated shSRBI MDA-MB-231 cells and shSRBI MDA-MB-231 cells treated with 
100 nM BLT-1 was also detected. This observation may be due to the presence of some 
residual SR-BI protein. Collectively, these data suggest that Akt activation may be mediated, 
in part, by SR-BI, and the downregulation of SR-BI is responsible for the observed reduction 
in the cellular proliferation. 
Inhibition of PI3K, not MEK1/2, inhibits growth of shCTL MDA-MB-231 
cells 
In order to elucidate the mechanism by which SR-BI knockdown inhibits proliferation, we 
used pharmacological agents to inhibit PI3K and MAPK signaling pathways. We show that 
the PI3K inhibitor, LY294002, abolished FBS-induced activation of Akt (Figure 5A) in 
shCTL and shSRBI MDA-MB-231 cells. Importantly, PI3K inhibition significantly reduced 
proliferation of shCTL MDA-MB-231 cells to levels similar to those observed with untreated 
shSRBI MDA-MB-231 cells (Figure 5B). In addition, PI3K inhibition had no effect on the 
proliferation of shSRBI MDA-MB-231 cells suggesting that downregulation of SR-BI in 
these cells was sufficient to inhibit proliferation. Conversely, U0126-induced inhibition of 
MEK1/2, which activates Erk1/2, did not affect proliferation of shCTL MDA-MB-231 or 
shSRBI MDA-MB-231 cells (Figure 5B). Erk1/2 activation, however, was significantly 
reduced by inhibition of MEK1/2 in both cell types (Figure 5A). These results suggest that 
the MAPK pathway does not play a significant role in SR-BI-mediated signaling and 
proliferation unlike the PI3K pathway. 
Figure 5 Inhibition of PI3K, not MEK1/2, prevents proliferation of MDA-MB-231 cells. 
A. LY294002 and U0126 effectively inhibit Akt and Erk1/2 activation in MDA-MB-231 
cells. Serum-starved shCTL and shSRBI MDA-MB-231 cells were incubated with or without 
the inhibitors LY294002 (15 µM) or U0126 (10 µM) for 2 hours. Medium containing 10% 
FBS was added for 30 minutes, cells were lysed, and whole cell lysates were analyzed by 
Western blot for the indicated proteins. GAPDH was used as a loading control. B. PI3K 
inhibition reduces cellular proliferation of shCTL MDA-MB-231 cells. shCTL and shSRBI 
MDA-MB-231 cells were incubated with culture media containing either LY294002 (15µM) 
or U0126 (10 µM) and 3H-thymidine for 6 hours, at which time the assay was stopped, and 
lysates were collected. Columns represent the mean 3H-thymidine incorporation (cpm/µg 
protein); bars represent ± SD. Results obtained from vehicle-treated (CTL) shCTL MDA-
MB-231 cells are significantly different from those obtained with shSRBI MDA-MB-231 
cells (**P<0.001, one-way ANOVA with Tukey’s post-test analysis). Results obtained from 
vehicle-treated shCTL MDA-MB-231 cells (CTL) are significantly different from those 
obtained with shCTL MDA-MB-231 cells treated with LY294002. Note that proliferation of 
shCTL MDA-MB-231 cells treated with U0126 was not significantly different from that 
observed with vehicle-treated shCTL MDA-MB-231 cells. Proliferation of shSRBI MDA-
MB-231 cells treated with LY294002 or U0126 was also not significantly different from that 
observed with vehicle-treated shCTL MDA-MB-231 cells. Results are representative of three 
independent experiments. 
Knockdown of SR-BI results in decreases in in vivo tumor growth of MDA-
MB-231 and MCF7 cells 
To assess the effect of SR-BI knockdown in vivo, we subcutaneously injected shSRBI and 
shCTL MDA-MB-231 cells in the flanks of nude mice. Four weeks after injection, tumors 
were excised from sacrificed mice, and mass and volume were measured. Tumors obtained 
with shCTL MDA-MB-231 were significantly larger than those obtained from shSRBI 
MDA-MB-231: tumor volume and mass were increased by 3.8 fold and 3.7 fold, respectively 
(Figure 6A). To determine the role of SR-BI in tumor growth in MCF7 cells, shCTL and 
shSRBI MCF7 cells (5 × 106) were orthotopically injected into the mammary fat pad of 
athymic nude mice after implantation with slow release 17β-estradiol pellets. Four weeks 
post-injection, mice were sacrificed, tumors were excised, and mass and volume of tumors 
were determined (Figure 6B). Tumors obtained with shCTL MCF7 were 1.5-fold larger than 
those obtained with shSRBI MCF7 (P<0.05), and 1.3-fold larger by mass (marginally 
significant). 
Figure 6 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. A. Knockdown 
of SR-BI in MDA-MB-231 cells decreases tumor growth in vivo. Athymic nude mice were 
injected with 106 MDA-MB-231 cells carrying control shRNA (shCTL) or shSRBI. Four 
weeks post-injection, mice were sacrificed, and tumors were excised. Tumors were weighed 
and volume determined using the formula (length x width2)/2. Columns represent the mean 
volume and mass respectively, bars represent ± SD. Tumors obtained with shCTL cells were 
significantly larger by weight and volume than the tumors obtained with shSRBI. (*P<0.05, 
n=14 shCTL, n=13 shSRBI) B. Knockdown of SR-BI in MCF7 cells decreases tumor growth 
in vivo. MCF7 cells (5×106) were orthotopically injected into the mammary fat pad of 9 
week-old athymic nude mice implanted with slow release 17β-estradiol pellets 
(0.36mg/pellet, 60 days). Four weeks post injection, mice were sacrificed, and the tumors 
were excised. Tumors were weighed and volume determined using the formula (length x 
width2)/2. Columns represent the mean volume and mass respectively; bars represent ± SD. 
The shCTL tumors were significantly larger by volume than the shSRBI tumors (*P<0.05, 
n=8 shCTL, n=7 shSRBI). C. shCTL tumors display increased expression of proliferative 
markers compared to shSRBI tumors. Immunohistochemistry was performed to determine 
expression patterns of SR-BI and pErk1/2 in MDA-MB231 tumors. D. shCTL tumors display 
increased expression of proliferative markers compared to shSRBI tumors. Three tumors per 
cell type were analyzed by western blot analysis for the indicated proteins. GAPDH was used 
as a loading control. 
To elucidate the mechanism by which SR-BI regulates tumor formation, tissue 
immunohistochemical analyses (Figure 6C) and immunoblot analyses of homogenized 
tumors (Figure 6D) were performed. Immunohistochemistry analyses demonstrated the 
reduction in SR-BI protein expression in shSRBI MDA-MB-231-derived tumors compared to 
shCTL MDA-MB231. Results also revealed that levels of the proliferative marker, pErk1/2, 
were decreased in shSRBI MDA-MB-231 tumors, compared to those observed in control 
tumors. Consistent with in vitro findings, pAkt levels were decreased in shSRBI MDA-MB-
231 tumors compared to those observed in control tumors. 
Since cholesterol has been shown to play a role in the regulation of angiogenesis [38], 
microvessel density in the tumors was assessed by staining tumor sections for CD31, a 
specific marker of endothelial cells (Figure 7A). A significant increase in microvessel density 
was observed with tumors obtained from shCTL MDA-MB-231 cells compared to those 
obtained from shSRBI MDA-MB-231 cells. These data suggest that SR-BI can regulate 
angiogenesis in these tumors. Finally, SR-BI has been shown to activate Akt [23], which may 
inhibit apoptosis thereby promoting cell survival [39]. Therefore, we assessed apoptosis by 
TUNEL staining in tissue sections obtained from shCTL and shSRBI MDA-MB-231 
xenograft tumors (Figure 7B). As anticipated, we observed a significant increase in apoptosis 
in shSRBI MDA-MB-231 tumors compared to shCTL MDA-MB-231 tumors. 
Figure 7 Knockdown of SR-BI inhibits xenograft tumor growth in vivo. A. Knockdown 
of SR-BI results in decreased angiogenesis in MDA-MB-231 xenograft tumors. 
Immunohistochemistry was performed to determine expression of CD31. CD31 staining was 
quantified by averaging the number of vessels per field in 5 separate fields per sample. 
Columns represent the mean microvessel density; bars represent ± SD. Microvessel density 
was statistically greater in shCTL MDA-MB-231 tumors compared to shSRBI MDA-MB-
231 cells (*P<0.05 student’s t test, n=4 per group). B. Knockdown of SR-BI results in 
increased apoptosis in MDA-MB-231 xenograft tumors. Images shown are representative of 
TUNEL assay staining. Percentage of TUNEL positive cells was calculated by dividing the 
number of TUNEL-positive cells by the total number of cells in 4 separate fields. Columns 
represent the percent of TUNEL-positive cells; bars represent ± SD. TUNEL staining is 
statistically increased in shSRBI MDA-MB-231 tumors compared to shCTL MDA-MB-231 
tumors (***P<0.001, student’s t test, shCTL n=3 and shSRBI n=4). 
Discussion 
In the present study, we have examined the role of HDL and its receptor, SR-BI, in breast 
cancer development and progression. We found that HDL3 stimulates migration and activates 
signaling pathways such as MAPK and PI3K in two breast cancer cell lines. Inhibiting 
selective HDL-cholesteryl ester uptake by knocking down or pharmacologically inhibiting 
SR-BI resulted in an attenuation of cell signaling events induced by HDL. Additionally, loss 
of SR-BI resulted in decreased proliferation, migration, and tumor growth of MDA-MB-231 
cells. These findings suggest that regulating cholesterol metabolism and cellular signaling 
pathways via SR-BI may be linked and may additionally identify new targets associated with 
tumor progression. 
HDL, signal transduction and cellular migration 
HDL has a well-established role in the etiology of atherosclerosis, particularly in reverse 
cholesterol transport whereby HDL removes excess cholesterol molecules from peripheral 
tissues and returns them to the liver for excretion or recycling [40]. In addition, HDL 
functions in a number of other cellular processes including inhibition of apoptosis in 
macrophages [41], induction of migration in endothelial cells [24], and the initiation of cell 
signaling events in multiple cells types [22,23,42]. Although clinical studies have suggested 
that plasma HDL levels may be correlated with increased breast cancer [5,7-9,12], the 
mechanisms by which HDL exerts its effect have yet to be elucidated. HDL has been shown 
to activate Erk1/2 in fibroblasts [23,42], Chinese hamster ovary cells [22], endothelial cells 
[23], and prostate cancer cells [35,43]. Studies have also shown that it can activate Akt in 
endothelial [23] and prostate cancer cells [35,43]. Interestingly, the activation of Erk1/2 [44] 
and Akt [39,45] has been implicated in several human cancers, including breast cancer. In the 
present study, we have established a role for HDL as a mediator of signal transduction in two 
breast cancer cell lines. Consistent with the results obtained in other cell types, we found that, 
in both MCF7 and MDA-MB-231 cells, incubation with HDL3 induces a rapid activation of 
both Erk1/2 and Akt signaling pathways. These novel findings in breast cancer suggest that 
HDL may regulate various signaling pathways and may therefore alter tumor progression. 
In the present study, we found that HDL can induce migration of two breast cancer cell lines, 
MCF7 and MDA-MB-231, suggesting that HDL may play a role in the early stages of 
metastasis. This finding is consistent with previous studies showing that HDL can stimulate 
migration of endothelial cells [24,46]. Interestingly, the observed migration was shown to be 
mediated by SR-BI [24]. By contrast, a recent study reported that HDL inhibits migration of 
MDA-MB-231 in Boyden chamber assays [14]. However, in this study, the investigators used 
serum as the chemoattractant, and HDL was added to the upper chamber, thereby measuring 
the ability of HDL to prevent cellular migration induced by serum. By contrast, our method 
allows the analysis of the role of HDL in the regulation of cellular migration and therefore 
allows a direct measurement of the capability of HDL to induce migration of MDA-MB-231 
cells. As a result, our results indicate that HDL may play a role in the pathogenesis of breast 
cancer, especially in the later stages. 
SR-BI, signal transduction regulation, and tumor formation 
SR-BI has been implicated as a mediator of several cell signaling events in the context of 
atherosclerosis [22,23,25-27]. Previous studies have shown that HDL binding to SR-BI and 
subsequent lipid transfer are sufficient to activate Src, which subsequently activates the 
PI3K/Akt and MAPK pathways [25,27]. In endothelial cells, one of the downstream effectors 
of Akt is eNOS, which catalyzes the production of NO. The results obtained in the present 
study are consistent with the hypothesis that SR-BI may also play a role in signal 
transduction in the context of cancer. In agreement with this hypothesis, upon knockdown or 
pharmacological inhibition of SR-BI in MDA-MB-231 cells, Akt activation was significantly 
reduced, suggesting that SR-BI may be mediating this response. In addition, down-regulation 
of SR-BI was accompanied by a reduction of total cholesterol levels in MDA-MB-231 cells. 
These results are consistent with reports that indicate that the cholesterol flux mediated by 
SR-BI plays a role in the regulation of signal transduction initiation [26]. In our model, 
decreased total cholesterol levels may represent a reduction in SR-BI-mediated cholesterol 
flux and therefore significantly reduce signal transduction activation. SR-BI also binds LDL, 
which can, like HDL, promote the cellular entry of cholesteryl ester. While LDL may 
promote the entry of cholesteryl ester via SR-BI, it is not sufficient to induce migration of 
breast cancer cells, and it does not appear to alter Akt activation (Figure 2C and D). Taken 
together, our data suggest that both cholesteryl ester entry via HDL-SR-BI and Akt activation 
are required for cellular proliferation and migration, and, eventually, tumor growth. 
Activation of the PI3K/Akt pathway promotes growth, survival, and proliferation [45] and 
has been implicated in a variety of human cancers [39]. Importantly, Akt is aberrantly hyper-
activated in approximately 40% of breast cancers [39]. Interestingly, we observed a reduction 
in proliferation and migration in the SR-BI-knockdown cells compared to control cells in 
association with reduced Akt activation. These results suggest that SR-BI may mediate the 
activation of Akt and its downstream effects in the presence of HDL. Mechanistically, we 
showed that the inhibition of the PI3K/Akt pathway results in significantly reduced 
proliferation of shCTL MDA-MB-231 cells similar to the reduction in proliferation observed 
in shSRBI MDA-MB-231 cells. Importantly, no further reduction in proliferation of shSRBI 
MDA-MB-231 cells was detected upon inhibition of the PI3K/Akt pathway. Taken together, 
these data suggest that reduced Akt activation observed in the shSRBI MDA-MB-231 cells 
may be responsible for reduced proliferation of these cells compared to shCTL MDA-MB-
231 cells. 
Previous studies have suggested a role for SR-BI in the etiology of breast cancer. Cao et al. 
[30] have shown that expression of SR-BI is increased in human breast tumors compared to 
the normal surrounding tissue. They also demonstrated that recombinant expression of a 
mutant form of SR-BI, which lacked the carboxyl-terminal tail of the protein, could inhibit 
proliferation of breast cancer cells. Their study further suggested that this effect was possibly 
due to reduced Akt activation. Our study is the first to demonstrate directly that Akt 
activation is reduced when SR-BI is knocked down or pharmacologically inhibited. 
Furthermore, in agreement with the previously mentioned study [30], we showed that 
proliferation of MDA-MB-231 cells was significantly inhibited by downregulation of SR-BI 
protein levels and by pharmacological inhibition of SR-BI. In addition, we observed that SR-
BI knockdown inhibits migration. This finding may suggest a role for SR-BI in the initiation 
of metastasis. Finally, we demonstrated that knockdown of SR-BI in MDA-MB-231 cells can 
lead to reduced tumor growth in vivo accompanied by increased activation of Erk1/2 and Akt, 
and an increase in cellular apoptosis. In MCF7 cells, knockdown of SR-BI also led to reduced 
xenograft tumor growth. 
Previous studies have shown that Akt can inhibit apoptosis through a variety of mechanisms 
including the phosphorylation of BAD, thus preventing cytochrome c release from 
mitochondria and the direct inhibition of the caspase activation cascade [39]. Increased 
cellular cholesterol levels have been shown to increase Akt activation and decrease apoptosis 
in prostate cancer cells [47]. Consistent with these observations, a recent study has shown 
that inhibition of xenograft tumor growth could be achieved with colon cancer cells that re-
express the ATP-binding cassette transporter A1 (ABCA1) [48]. ABCA1 is a lipid transporter 
that mediates the efflux of cellular cholesterol to lipid free apolipoprotein A-I [49]. 
Furthermore, in this study, re-expression of ABCA1 resulted in decreased mitochondrial 
cholesterol content and increased release of cytochrome c, which ultimately led to increased 
apoptosis. Our work also indicated that SR-BI knockdown can significantly reduce apoptosis 
in xenograft tumors as shown by TUNEL staining. Consequently, a reduction in the levels of 
cellular cholesterol content may be responsible, at least in part, for the decreased apoptosis 
observed in our model. Taken together, these data also suggest an important role for 
cholesterol in the regulation of cellular signaling pathways and tumor formation. Importantly, 
excess cellular cholesterol accumulates in the form of esterified cholesterol. Previous works 
and ours suggest that the accumulation of esterified cholesterol may lead to a modification of 
signaling pathways associated with proliferation and migration in tumors. Consistent with 
this hypothesis, increasing cellular esterified cholesterol levels have been shown to induce 
cellular proliferation and enhance invasiveness of tumor cell lines [50]. Conversely, the 
inhibition of cholesterol esterification has been shown to have the reverse effect [51,52]. 
Conclusions 
In summary, our results suggest that HDL and SR-BI have pro-oncogenic activity and can 
induce migration and activate signal transduction pathways responsible for cellular 
proliferation and tumor formation in two breast cancer cell lines. Additionally, knockdown or 
pharmacological inhibition of SR-BI could attenuate signaling mediated by HDL and inhibit 
proliferation, migration, and tumor growth. Taken together, these findings identify SR-BI and 
HDL as potential therapeutic targets for the treatment of breast cancer. 
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